This study is completed in the United States, in Bulgaria, in Czechia, .... It is testing 3 Dose Levels of TAK-831 for schizophrenia.
SchizophreniaDrugFrom 18 Years to 60 Years
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Then choose your country and confirm availability with each study site.
In plain English
Key information made simple
What is this study testing?
This study is testing whether Luvadaxistat may be useful for adults experiencing schizophrenia.
What would participation involve?
Participants may receive Luvadaxistat, attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group. The registry lists locations in Bulgaria, in Czechia, and in Germany.
Who is it mainly for?
This study appears to be mainly for adults with schizophrenia.
What should you check before joining?
Ask about the dose, safety monitoring, and possible side effects, whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.
Your next step
Check the study details
Check the official source, then confirm these points with the research team.
Where are visits, can any be remote, and how much time is needed?
Costs and support
What costs, reimbursement or compensation apply?
Before joining
Questions to ask before joining
What are the exact eligibility criteria, and what could exclude someone?
How many visits, assessments, or follow-ups are expected, and over what period?
What risks, side effects, practical burdens, or alternatives should be understood first?
Who should be contacted to confirm locations, timing, compensation, and next steps?
Study clarity
Things to check before joining
Study start dateStarted: January 4, 2018
Recruitment status
Completed
Enrollment listed in the registry
256
Sponsor
Neurocrine Biosciences
Sponsor type
Biotech company
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States, Bulgaria, Czechia, ...
Age range
From 18 Years to 60 Years
Official registry ID
NCT03382639
Official title
A Phase 2, 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of 3 Dose Levels of TAK-831 in Adjunctive Treatment of Adult Subjects With Negative Symptoms of Schizophrenia
Ask HopeStage to help me review this study
This record does not confirm open recruitment. We can help you understand it and explore other studies.
Study ID: NCT03382639. We help you review the study, but cannot decide medical eligibility.
Check recruitment and locations
Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.
Semel Institute for Neuroscience and Human Behavior
Los Angeles, California
Site status: Not listed — confirm with the team
Excell Research
Oceanside, California
Site status: Not listed — confirm with the team
NRC Research Institute
Orange, California
Site status: Not listed — confirm with the team
Artemis Institute for Clinical Research, LLC
San Diego, California
Site status: Not listed — confirm with the team
Connecticut Mental Health Center - Yale University
New Haven, Connecticut
Site status: Not listed — confirm with the team
Atlanta Center for Medical Research
Atlanta, Georgia
Site status: Not listed — confirm with the team
Augusta University
Augusta, Georgia
Site status: Not listed — confirm with the team
The Dr. Alan & Diane Breier Prevention and Recovery Center for Early Psychosis
Indianapolis, Indiana
Site status: Not listed — confirm with the team
Center for Behavioral Health, LLC
Gaithersburg, Maryland
Site status: Not listed — confirm with the team
Cherry Health
Grand Rapids, Michigan
Site status: Not listed — confirm with the team
Manhattan Psychiatric Center
New York, New York
Site status: Not listed — confirm with the team
Research Strategies of Memphis, LLC
Memphis, Tennessee
Site status: Not listed — confirm with the team
Community Clinical Research, Inc.
Austin, Texas
Site status: Not listed — confirm with the team
Core Clinical Research
Everett, Washington
Site status: Not listed — confirm with the team
In practice
For you
Participation may contribute to research. Personal benefit is not guaranteed.
Ask the research team to explain the activities, time commitment, and follow-up involved.
Study sites are listed. Confirm the relevant site and any travel before making plans.
Important
Not medical advice
Information from public sources.
Are you the study sponsor? Contact us to update this page: hi@hopestage.com
FAQ
Questions about this study
What is this study trying to understand?
This study is exploring medication or study treatment for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Does this study involve a medication?
This appears to be a medication / drug study involving Luvadaxistat, Placebo. Phase 2 studies usually explore whether the intervention may work, while continuing to monitor safety.
Who might this study be for?
This study may concern people with schizophrenia; age range: From 18 Years to 60 Years. The criteria appear fairly specific, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
What side effects, interactions, or treatment changes should I check?
If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by Neurocrine Biosciences, which appears to be a biotech company. Sponsor website: https://www.neurocrine.com. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Explore other studies
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
